Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy.
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ adverse effects
Bifidobacterium longum
Diclofenac
/ adverse effects
Feces
/ chemistry
Hemoglobins
Ileum
/ microbiology
Intestinal Diseases
/ chemically induced
Intestinal Mucosa
Lactoferrin
/ administration & dosage
Leukocyte L1 Antigen Complex
/ analysis
Male
Malondialdehyde
/ metabolism
NF-kappa B
Peroxidase
/ metabolism
Prebiotics
/ administration & dosage
Probiotics
/ administration & dosage
Protective Agents
/ administration & dosage
Rats
Signal Transduction
Toll-Like Receptor 2
/ metabolism
Toll-Like Receptor 4
/ metabolism
Bifidobacterium longum
Intestinal damage
Lactoferrin
Nonsteroidal anti-inflammatory drugs
Prebiotics
Probiotics
Journal
Nutrition (Burbank, Los Angeles County, Calif.)
ISSN: 1873-1244
Titre abrégé: Nutrition
Pays: United States
ID NLM: 8802712
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
22
02
2019
revised:
29
08
2019
accepted:
30
08
2019
pubmed:
19
11
2019
medline:
1
1
2021
entrez:
19
11
2019
Statut:
ppublish
Résumé
Nonsteroidal anti-inflammatory drugs can exert detrimental effects in the lower digestive tract. The aim of this study was to examine the protective effects of a combination of the probiotic Bifidobacterium longum BB536 (Bifidobacterium) with the prebiotic lactoferrin in a rat model of diclofenac-induced enteropathy. Enteropathy was induced in 40-wk-old male rats by intragastric diclofenac (4 mg/kg twice daily for 14 d). Lactoferrin (100 mg/kg twice daily), Bifidobacterium (2.5 × 10 Diclofenac induced intestinal damage, along with increments of MPO and MDA, overexpression of TLR-2, TLR-4, MyD88, and NF-κB p65, increased fecal calprotectin and decreased blood hemoglobin levels. Lactoferrin or Bifidobacterium alone prevented diclofenac-induced enteric damage, and the changes in blood hemoglobin, MPO, MDA, fecal calprotectin, and NF-κB p65. Bifidobacterium, but not lactoferrin, decreased TLR-4 expression, although none of them affected MyD88 overexpression. TLR-2 expression was slightly enhanced by all treatments. The combined administration of lactoferrin and Bifidobacterium reduced further the intestinal damage, and restored MPO and blood hemoglobin levels. Diclofenac induced ileal mucosal lesions by activation of inflammatory and pro-oxidant mechanisms. These detrimental actions were prevented by the combination of lactoferrin with Bifidobacterium likely through the modulation of TLR-2/-4/NF-κB proinflammatory pathways.
Identifiants
pubmed: 31739175
pii: S0899-9007(19)30167-4
doi: 10.1016/j.nut.2019.110583
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Hemoglobins
0
Leukocyte L1 Antigen Complex
0
NF-kappa B
0
Prebiotics
0
Protective Agents
0
Tlr2 protein, rat
0
Tlr4 protein, rat
0
Toll-Like Receptor 2
0
Toll-Like Receptor 4
0
Diclofenac
144O8QL0L1
Malondialdehyde
4Y8F71G49Q
Peroxidase
EC 1.11.1.7
Lactoferrin
EC 3.4.21.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110583Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.